25 Oct 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Dx assays, Singapore-based provider of contract development services to the global diagnostics, pharmaceutical and biotechnology industries, launched an unique fee for service companion diagnostic development initiative providing the pharmaceutical companies maximum ownership and control in development, launch and marketing.
The initiative comes as a response to a growing demand from some pharmaceutical companies for full control over the whole process, from discovery and development to marketing and sales of both the drug and the companion diagnostic.
"The feedback we have had is that pharmaceutical companies are facing a risk in traditional companion diagnostic co-development deals. Millions of dollars are spent on drug development but, for successful commercialization, they are fully dependent on an external diagnostic partner for launching and marketing the companion diagnostic. The Dx assays model gives the control back to the pharmaceutical companies." says Dr John Thornback, CEO, Dx assays.
Dx assays has the capabilities to develop highly generic companion diagnostics, but can also develop specific assays tailored to the needs of a proprietary drug. Since establishment in 2008, Dx assays has carried out over 90 different projects in the field of biomarker assay, companion diagnostic and molecular diagnostic development for different pharmaceutical, diagnostic and biotech customers.
Dx assays offers a total package from initial assay development for genetic biomarkers all the way to support in assay validation for clinical trials and assistance in manufacturing and regulatory approval.